<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03686124</url>
  </required_header>
  <id_info>
    <org_study_id>IMA203-101</org_study_id>
    <nct_id>NCT03686124</nct_id>
  </id_info>
  <brief_title>TCR-engineered T Cells in Solid Tumors</brief_title>
  <acronym>ACTengine</acronym>
  <official_title>Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Atezolizumab in Patients With Recurrent and/or Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immatics US, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immatics US, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study purpose is to establish the safety and tolerability of IMA203 product with or&#xD;
      without combination with atezolizumab in patients with solid tumors that express&#xD;
      preferentially expressed antigen in melanoma (PRAME).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SCREENING: Patient eligibility will be determined by protocol inclusion/exclusion criteria&#xD;
      including HLA (human leukocyte antigen) screening and a biopsy for biomarker screening. If&#xD;
      the patient is eligible, white blood cells will be taken during leukapheresis for the&#xD;
      manufacture of the IMA203 product.&#xD;
&#xD;
      MANUFACTURING: IMA203 product will be made from the patient's white blood cells.&#xD;
&#xD;
      TREATMENT: Lymphodepletion with cyclophosphamide and fludarabine will occur in the days&#xD;
      before the IMA203 product infusion to improve the duration of time that IMA203 product stays&#xD;
      in the body. The patient will be admitted to the hospital during the T-cell infusion.&#xD;
&#xD;
      After the IMA203 product infusion, a low dose of IL-2 will be given subcutaneously daily for&#xD;
      10 days.&#xD;
&#xD;
      In Extension Cohort B (IMA203 plus atezolizumab), atezolizumab will be administered for up to&#xD;
      one year.&#xD;
&#xD;
      Patients will be monitored closely throughout the study. The treatment and observation phase&#xD;
      ends 3 years post infusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 14, 2019</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AE)</measure>
    <time_frame>up to 3 years post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Persistence of T-cells</measure>
    <time_frame>up to 3 years post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 and immune-related RECIST (irRECIST)</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Refractory Cancer</condition>
  <condition>Recurrent Cancer</condition>
  <condition>Solid Tumor, Adult</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of IMA203</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extension Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMA203 at MTD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extension Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMA203 at MTD + atezolizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMA203 Product</intervention_name>
    <description>The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Extension Cohort A</arm_group_label>
    <arm_group_label>Extension Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IMADetect®</intervention_name>
    <description>IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in Immatics clinical trials. IMADetect® is intended for investigational use only.</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Extension Cohort A</arm_group_label>
    <arm_group_label>Extension Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab will be given post IMA203 infusion, after hematologic recovery is achieved, for up to a year after IMA203 infusion.</description>
    <arm_group_label>Extension Cohort B</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed advanced and/or metastatic solid tumor&#xD;
&#xD;
          -  Patients may enter screening procedure before, during, or after the last available&#xD;
             indicated standard of care treatment. There is no limitation for prior anti cancer&#xD;
             treatments.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
          -  HLA phenotype positive for the study&#xD;
&#xD;
          -  Measurable disease and accessible to biopsy&#xD;
&#xD;
          -  Adequate pulmonary function per protocol&#xD;
&#xD;
          -  Adequate organ and bone marrow function per protocol&#xD;
&#xD;
          -  Acceptable coagulation status per protocol&#xD;
&#xD;
          -  Adequate hepatic function per protocol&#xD;
&#xD;
          -  Adequate renal function per protocol&#xD;
&#xD;
          -  Patient's tumor must express tumor antigen by qPCR using a fresh tumor biopsy specimen&#xD;
&#xD;
          -  Life expectancy more than 3 months&#xD;
&#xD;
          -  Confirmed availability of production capacities for IMA203 product&#xD;
&#xD;
          -  Patients must have recurrent/progressing and/or refractory solid tumors and must have&#xD;
             received or not be eligible for all available indicated standard of care treatment.&#xD;
&#xD;
          -  For hepatocellular carcinoma (HCC) patients only, Child-Pugh score of ≤ 6&#xD;
&#xD;
          -  IMA203 product must have passed all of the release tests&#xD;
&#xD;
          -  Female patient of childbearing potential must use adequate contraception prior to&#xD;
             study entry until 12 months after the infusion of IMA203&#xD;
&#xD;
          -  Male patient must agree to use effective contraception or be abstinent while on study&#xD;
             and for 6 months after the infusion of IMA203&#xD;
&#xD;
          -  Hepatocellular carcinoma (HCC) patients with liver cirrhosis only - upper endoscopy is&#xD;
             required within 6 months of study entry&#xD;
&#xD;
          -  The patient must have recovered from any side effects of prior therapy to Grade 1 or&#xD;
             lower (except for non-clinically significant toxicities; e.g., alopecia, vitiligo)&#xD;
             prior to lymphodepletion. As determined by the investigator, the patient may still be&#xD;
             eligible if the patient has not fully recovered from Grade ≥ 2 toxicities if these&#xD;
             toxicities are not anticipated to further improve (e.g., chronic neuropathy) and such&#xD;
             toxicities are not anticipated to worsen with the lymphodepletion therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of other malignancies (except for adequately treated basal or squamous cell&#xD;
             carcinoma or carcinoma in situ) within the last 3 years&#xD;
&#xD;
          -  Solid tumors with low likelihood of tumor biomarker expression per protocol&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Serious autoimmune disease Note: At the discretion of the investigator, these patients&#xD;
             may be included if their disease is well controlled without the use of&#xD;
             immunosuppressive agents.&#xD;
&#xD;
          -  History of cardiac conditions as per protocol&#xD;
&#xD;
          -  Prior stem cell transplantation or solid organ transplantation&#xD;
&#xD;
          -  Concurrent severe and/or uncontrolled medical disease that could compromise&#xD;
             participation in the study&#xD;
&#xD;
          -  History of hypersensitivity to cyclophosphamide (CY), fludarabine (FLU), or IL-2 or&#xD;
             any of these rescue medications&#xD;
&#xD;
          -  History of or current immunodeficiency disease or prior treatment compromising immune&#xD;
             function at the discretion of the treating physician&#xD;
&#xD;
          -  HIV infection, active hepatitis B virus (HBV), active hepatitis C virus (HCV)&#xD;
             infection, ongoing active anti-HCV treatment or detectable HBV or HCV viral load at&#xD;
             the most recent laboratory report. Patients with both HBV and HCV infections will be&#xD;
             excluded from screening&#xD;
&#xD;
               1. Patients with a history of HCV infection and with an undetectable viral load per&#xD;
                  the most recent laboratory report and/or completed anti-HCV treatment but are HCV&#xD;
                  antibody positive are permitted.&#xD;
&#xD;
               2. History of treated HBV infection is permitted if the viral load is undetectable&#xD;
                  per the most recent laboratory report. Note: HCC patients with controlled HBV&#xD;
                  infection, as defined by resolved (anti-hepatitis B surface antigen [HBs-Ag]&#xD;
                  antibody (Ab) negative, anti-core antigen [HBc Ag] Ab positive) or chronic stable&#xD;
                  (anti HBs-Ag Ab positive) HBV infection will be eligible for screening. Patients&#xD;
                  with active HBV infection who are not on anti-HBV treatment will be excluded.&#xD;
&#xD;
          -  Any condition contraindicating leukapheresis, lymphodepletion, low-dose IL-2, and/or&#xD;
             IMA203 treatment&#xD;
&#xD;
          -  Patients with active brain metastases&#xD;
&#xD;
        NOTE: Patients with a history of brain metastases may be eligible, if an imaging scan with&#xD;
        contrast enhancement not older than 4 weeks is able to exclude the existence of currently&#xD;
        active brain metastasis, and steroid therapy has been discontinued for ≥2 weeks.&#xD;
&#xD;
          -  Treatment with protocol-defined excluded treatments, medical devices, and/or&#xD;
             procedures per protocol&#xD;
&#xD;
          -  Concurrent participation in an interventional part of another clinical trial.&#xD;
&#xD;
        For atezolizumab treatment, patients must have adequate hematologic recovery, must have&#xD;
        recovered from infections to Grade 1 or lower, and must not have a history of severe&#xD;
        immune-related toxicities, defined as any Grade 3 or 4 toxicities related to prior&#xD;
        PD1/PD-L1 inhibitor therapy (e.g., atezolizumab, pembrolizumab or nivolumab etc.).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cedrik Britten, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Immatics US, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jorge Rivas, M.D., Ph.D.</last_name>
    <phone>346-204-5350</phone>
    <email>ctgovinquiries@immatics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>212-342-5162</phone>
      <email>cancerclinicaltrials@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Ran Reshef, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Luke, M.D.</last_name>
      <phone>412-623-6132</phone>
      <email>lukejj@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Luke, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dejka M Araujo, M.D.</last_name>
      <phone>713-792-3626</phone>
      <email>daraujo@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Dejka M Araujo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg, Franz-Josef-Strauß-Allee 11</name>
      <address>
        <city>Regensburg</city>
        <state>Bavaria</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Heudobler, MD</last_name>
      <phone>+49 (0)941 944-14800</phone>
      <email>daniel.heudobler@ukr.de</email>
    </contact>
    <investigator>
      <last_name>Daniel Heudobler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <state>Bavaria</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>chatterjee_m@ukw.de</email>
    </contact>
    <contact_backup>
      <phone>+49 (0)931 201 40953</phone>
    </contact_backup>
    <investigator>
      <last_name>Manik Chatterjee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn - Medizinische Klinik III</name>
      <address>
        <city>Bonn</city>
        <state>North Rhine-Westphalia</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 (0)228 287-17233</phone>
      <email>tobias.holderried@ukbonn.de</email>
    </contact>
    <contact_backup>
      <phone>+49 (0)151 44048451</phone>
    </contact_backup>
    <investigator>
      <last_name>Tobias Holderried, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum C.-G.-Carus Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 (0)351 458 7566</phone>
      <email>Martin.Wermke@uniklinikum-dresden.de</email>
    </contact>
    <investigator>
      <last_name>Martin Wermke, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 (0)40 7410 - 52960</phone>
      <email>c.bokemeyer@uke.de</email>
    </contact>
    <contact_backup>
      <phone>+49 (0)40 7410 - 53962</phone>
    </contact_backup>
    <investigator>
      <last_name>Carsten Bokemeyer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 25, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2018</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T-cell therapy</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

